<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003245</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066124</org_study_id>
    <secondary_id>MDA-DM-97182</secondary_id>
    <secondary_id>NCI-T97-0103</secondary_id>
    <secondary_id>DM97-182</secondary_id>
    <nct_id>NCT00003245</nct_id>
  </id_info>
  <brief_title>Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Study of Irinotecan for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with&#xD;
      recurrent or refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate and toxicity of irinotecan when administered to&#xD;
           patients with recurrent or refractory non-Hodgkin's lymphoma.&#xD;
&#xD;
      OUTLINE: Patients are stratified by disease category (aggressive vs indolent vs mantle cell&#xD;
      lymphoma). Patients with aggressive and indolent lymphoma are further stratified as to being&#xD;
      refractory (no complete response (CR) or partial response (PR) to initial therapy) vs&#xD;
      recurrent (CR or PR to initial therapy); i.e, the following subcategories are used:&#xD;
&#xD;
        -  Stratum I:Refractory aggressive non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
        -  Stratum II:Recurrent aggressive NHL&#xD;
&#xD;
        -  Stratum III: Refractory indolent NHL&#xD;
&#xD;
        -  Stratum IV: Recurrent indolent NHL&#xD;
&#xD;
        -  Stratum V: Mantle cell NHL All patients receive irinotecan intravenously every 21 days.&#xD;
           Patients achieving CR or PR receive 6 courses. Patients may receive bone marrow&#xD;
           transplantation after at least 2 courses.&#xD;
&#xD;
      Patients are followed every 3 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue 18 patients per stratum; if at least three patients&#xD;
      respond, an additional 25 patients will be accrued for a total of 43 evaluable patients per&#xD;
      stratum. The total number accrued will be 90-215 over a period of approximately 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 1998</start_date>
  <completion_date type="Actual">July 30, 2004</completion_date>
  <primary_completion_date type="Actual">July 30, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">50</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent or refractory non-Hodgkin's lymphoma&#xD;
&#xD;
               -  First relapse requires histologic confirmation of relapse&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  No lymphomatous meningitis&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  15-75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Unless due to lymphoma:&#xD;
&#xD;
               -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
               -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
               -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN&#xD;
             if liver involvement)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Baseline calcium less than 12 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within 6 months&#xD;
&#xD;
          -  No congestive heart failure requiring therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus (i.e., random blood sugar of at least 250 mg)&#xD;
&#xD;
          -  No other concurrent severe disease&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No psychoses&#xD;
&#xD;
          -  No prior malignancy except for adequately treated basal cell or squamous cell skin&#xD;
             cancer or in situ cancer of the cervix unless surgically treated and disease free for&#xD;
             at least 5 years&#xD;
&#xD;
          -  Not pregnant or lactating&#xD;
&#xD;
          -  Effective contraception required of fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior bone marrow transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for treatment of lymphoma&#xD;
&#xD;
          -  No prior irinotecan, topotecan or aminocamptothecin&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  Radiotherapy that is not a part of a combined-modality therapy is counted as a regimen&#xD;
             (see Chemotherapy)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No phenytoin, phenobarbital, or other antiepileptic prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Goy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 23, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2003</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

